Suven Life Sciences Limited

Suven Life Sciences Limited

Suven Life Sciences Limited held its 37th Annual General Meeting (AGM) on August 25, 2026, through video conferencing. The meeting was attended by 152 members, and the requisite quorum was present. The Chairman informed the members that the Auditors' Report and Secretarial Audit report did not contain any adverse remarks. The members were further informed that the notice convening the 37th AGM together with audited financial statements for the year ended March 31, 2026, Report of Directors and Auditor's report had been sent to the Members through emails. Remote e-voting was commenced at 9:00 a.m. on Friday, August 21st, 2026, and concluded at 5:00 p.m. on Monday, August 24th, 2026.

Suven Life Sciences Limited

Suven Life Sciences Limited has received a Monitoring Agency Report from Crisil Ratings Limited for the quarter ended June 30, 2026, regarding the utilization of proceeds of the Preferential Issue of the Company.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication regarding un-audited financial results for the quarter ended June 30, 2026. The results are available on the company's website and stock exchanges.

Suven Life Sciences Limited

Suven Life Sciences Limited has announced its un-audited financial results for the quarter ended June 30, 2026, with a net loss of Rs. 12,76,03 lakhs and a total comprehensive loss of Rs. 12,76,03 lakhs.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about the notice of the 37th Annual General Meeting (AGM) and e-voting information. The AGM will be held on August 25, 2026, through video conferencing, and the notice along with the annual report 2025-26 has been sent to the members through electronic mode.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about Letter to Shareholders regarding Annual Report 2025-26, providing web-link to access the report on the Company's website.

Suven Life Sciences Limited

Suven Life Sciences Limited has submitted its Business Responsibility and Sustainability Report for FY 2025-26, as required by SEBI regulations.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 25, 2026.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about a newspaper publication regarding a special window for re-lodgment of transfer requests of physical shares.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about a scheduled meeting with investors and analysts on July 17, 2026, in Mumbai. The meeting will be in-person and will not include any unpublished price-sensitive information.

Suven Life Sciences Limited

Suven Life Sciences to present five scientific posters at Alzheimer's Association International Conference (AAIC) 2026, including updates on its ongoing global Phase-3 Masupirdine study and Usmarapride Phase-2 clinical development program.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about the revised outcome of its Board Meeting, including the allotment of 1,85,70,133 equity shares on a preferential basis, the re-appointment of an Independent Director, and the incorporation of a wholly-owned subsidiary in Singapore.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about the incorporation of a wholly-owned subsidiary in Singapore, along with the re-appointment of an independent director and the conversion of warrants into equity shares.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange about re-appointment of Dr. Vajja Sambasiva Rao effective from January 21, 2027 for a second term of 5 (five) years. The company has also approved the conversion of 1,85,70,133 fully paid warrants into equity shares, and issued and allotted 1,85,70,133 (One Crore Eighty-Five Lakhs Seventy Thousand One Hundred thirty-three only) Equity Shares of Rs.1/- each to various non-promoter persons/entities at an issue price of Rs. 134/- per share on preferential basis.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange regarding allotment of 18570133 securities pursuant to Convertible Securities at its meeting held on July 08, 2026. The company has received 100% consideration amount aggregating to Rs. 248,83,97,822/- in compliance with SEBI (ICDR) Regulations, 2018. The paid-up equity share capital of the company stands increased to Rs. 28,25,62,686/-.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on July 08, 2026. The Board of Directors has approved the allotment of 1,85,70,133 Equity Shares of the Company on preferential basis upon conversion of 1,85,70,133 fully paid warrants. The company has also re-appointed Dr. Vajja Sambasiva Rao as Non-Executive Independent Director for a second term of Five (5) years and incorporated a wholly-owned subsidiary in Singapore.

Suven Life Sciences Limited

Suven Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. The Trading Window for dealing in securities of the Company will remain closed from July 1, 2026, till the end of 48 hours after the declaration of un-audited Financial Results for the quarter ended June 30, 2026.

Suven Life Sciences Limited

Suven Life Sciences Limited has allotted 2,71,970 equity shares under its SLSL ESOP 2020 Scheme to eligible employees. The shares were issued at an exercise price of Rs. 55 each, leading to a capital inflow of approximately Rs. 1.49 crore. Following this allotment, the company's paid-up equity share capital increased from 26,37,20,583 shares to 26,39,92,553 shares. This is a procedural update regarding employee stock option exercise.

Suven Life Sciences Limited

Suven Life Sciences announced its participation in the BIO International Convention 2026 to showcase its differentiated Central Nervous System (CNS) clinical candidates. The company aims to explore strategic partnering, out-licensing, and co-development initiatives for its late-stage clinical assets, including Masupirdine and Samelisant (both in Phase 3) and Ropanicant, which recently reported positive Phase 2b results. Senior management will engage in numerous pre-scheduled meetings with global pharmaceutical and biotechnology companies.